Solid Biosciences (SLDB) Free Cash Flow (2017 - 2026)
Solid Biosciences (SLDB) reported Free Cash Flow of -$47.4 million for Q1 2026, down 48.22% on a YoY basis from -$91.5 million in Q1 2025, and up 10.6% sequentially from -$53.0 million in Q4 2025.
Solid Biosciences (SLDB) Free Cash Flow (2017 - 2026) Analysis & Trends
Solid Biosciences (SLDB) has 10 years of Free Cash Flow data on file, last reported at -$47.4 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow fell 48.22% year-over-year to -$47.4 million; the trailing twelve-month figure through Mar 2026 stood at -$171.8 million (down 60.07% YoY), and the FY2025 full-year result was -$156.3 million, down 55.3% from the prior year.
- Free Cash Flow climbed to -$47.4 million in Q1 2026, from -$53.0 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$17.0 million in Q2 2022 to a low of -$53.0 million in Q4 2025.
- A 5-year average of -$29.3 million and a median of -$27.4 million in 2022 frame the typical range for Free Cash Flow.
- Across the five-year window, Free Cash Flow surged 35.79% in 2023 and tumbled 75.17% in 2025, its largest moves.
- Tracing SLDB's Free Cash Flow over 5 years: stood at -$34.8 million in 2022, then jumped by 35.79% to -$22.3 million in 2023, then plunged by 35.48% to -$30.3 million in 2024, then plunged by 75.17% to -$53.0 million in 2025, then climbed by 10.6% to -$47.4 million in 2026.
- Business Quant data shows SLDB's Free Cash Flow at -$47.4 million in Q1 2026, -$53.0 million in Q4 2025, and -$34.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | Solid Biosciences | 529.40 Mn | 529.40 Mn | - | -47.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -47.40 Mn |
| Mar 31, 2026 | -47.40 Mn |
| Dec 31, 2025 | -53.01 Mn |
| Dec 31, 2025 | -53.01 Mn |
| Sep 30, 2025 | -34.06 Mn |
| Sep 30, 2025 | -34.06 Mn |
| Jun 30, 2025 | -37.29 Mn |
| Jun 30, 2025 | -37.29 Mn |
| Mar 31, 2025 | -31.98 Mn |
| Mar 31, 2025 | -31.98 Mn |
| Dec 31, 2024 | -30.26 Mn |
| Dec 31, 2024 | -30.26 Mn |
| Sep 30, 2024 | -23.31 Mn |
| Sep 30, 2024 | -23.31 Mn |
| Jun 30, 2024 | -21.75 Mn |
| Jun 30, 2024 | -21.75 Mn |
| Mar 31, 2024 | -25.34 Mn |
| Mar 31, 2024 | -25.34 Mn |
| Dec 31, 2023 | -22.34 Mn |
| Dec 31, 2023 | -22.34 Mn |